Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Voluntary Exercise Improves Estrous Cyclicity in Prenatally Androgenized Female Mice Despite Programming Decreased Voluntary Exercise: Implications for Polycystic Ovary Syndrome (PCOS).

Endocrinology | 2015

Prenatal androgen (PNA) exposure in mice produces a phenotype resembling lean polycystic ovary syndrome. We studied effects of voluntary exercise on metabolic and reproductive parameters in PNA vs vehicle (VEH)-treated mice. Mice (8 wk of age) were housed individually and estrous cycles monitored. At 10 weeks of age, mice were divided into groups (PNA, PNA-run, VEH, VEH-run, n = 8-9/group); those in the running groups received wheels allowing voluntary running. Unexpectedly, PNA mice ran less distance than VEH mice; ovariectomy eliminated this difference. In ovary-intact mice, there was no difference in glucose tolerance, lower limb muscle fiber types, weight, or body composition among groups after 16 weeks of running, although some mitochondrial proteins were mildly up-regulated by exercise in PNA mice. Before running, estrous cycles in PNA mice were disrupted with most days in diestrus. There was no change in cycles during weeks 1-6 of running (10-15 wk of age). In contrast, from weeks 11 to 16 of running, cycles in PNA mice improved with more days in proestrus and estrus and fewer in diestrus. PNA programs reduced voluntary exercise, perhaps mediated in part by ovarian secretions. Exercise without weight loss improved estrous cycles, which if translated could be important for fertility in and counseling of lean women with polycystic ovary syndrome.

Pubmed ID: 26360506 RIS Download

Associated grants

  • Agency: NICHD NIH HHS, United States
    Id: P50HD028934
  • Agency: NICHD NIH HHS, United States
    Id: P50 HD028934
  • Agency: NIH HHS, United States
    Id: K26 OD016502
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK020572
  • Agency: NIH HHS, United States
    Id: OD016502

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


GAPDH (D16H11) XP Rabbit mAb (antibody)

RRID:AB_10622025

This monoclonal targets GAPDH

View all literature mentions

AMPK alpha (D5A2) Rabbit mAb (antibody)

RRID:AB_10622186

This monoclonal targets AMPK alpha

View all literature mentions

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (antibody)

RRID:AB_2315112

This monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

View all literature mentions

Anti-Laminin antibody produced in rabbit (antibody)

RRID:AB_477163

This polyclonal targets Laminin antibody produced in rabbit

View all literature mentions